SG11201702122RA - Treatment of tumours using peptide-protein conjugates - Google Patents

Treatment of tumours using peptide-protein conjugates

Info

Publication number
SG11201702122RA
SG11201702122RA SG11201702122RA SG11201702122RA SG11201702122RA SG 11201702122R A SG11201702122R A SG 11201702122RA SG 11201702122R A SG11201702122R A SG 11201702122RA SG 11201702122R A SG11201702122R A SG 11201702122RA SG 11201702122R A SG11201702122R A SG 11201702122RA
Authority
SG
Singapore
Prior art keywords
tumours
peptide
treatment
protein conjugates
conjugates
Prior art date
Application number
SG11201702122RA
Inventor
Ruth Ganss
Anna Johansson
Original Assignee
Univ Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Australia filed Critical Univ Western Australia
Publication of SG11201702122RA publication Critical patent/SG11201702122RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
SG11201702122RA 2014-09-16 2015-09-16 Treatment of tumours using peptide-protein conjugates SG11201702122RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051090P 2014-09-16 2014-09-16
PCT/AU2015/050553 WO2016041014A1 (en) 2014-09-16 2015-09-16 Treatment of tumours using peptide-protein conjugates

Publications (1)

Publication Number Publication Date
SG11201702122RA true SG11201702122RA (en) 2017-04-27

Family

ID=55532343

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702122RA SG11201702122RA (en) 2014-09-16 2015-09-16 Treatment of tumours using peptide-protein conjugates

Country Status (7)

Country Link
US (2) US20160206691A1 (en)
EP (1) EP3194451A4 (en)
JP (1) JP2017534674A (en)
KR (1) KR20170090406A (en)
CN (1) CN107001484A (en)
SG (1) SG11201702122RA (en)
WO (1) WO2016041014A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150283237A1 (en) * 2014-04-02 2015-10-08 Mitchell S. Felder Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer
WO2018207115A1 (en) * 2017-05-10 2018-11-15 Fondazione Centro San Raffaele Tumor-homing peptides, conjugation products thereof and their use in diagnostic and therapy
CN110194800B (en) * 2018-02-26 2022-11-18 张灏 Fusion protein, extracellular exosome and tumor vaccine and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263081B2 (en) * 2007-05-14 2012-09-11 The University Of Chicago Antibody-light fusion products for cancer therapeutics
WO2011139629A2 (en) * 2010-04-26 2011-11-10 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
MX2014009289A (en) * 2012-02-01 2015-09-08 Compugen Ltd C10rf32 antibodies, and uses thereof for treatment of cancer.
SG10201700340WA (en) * 2012-02-27 2017-03-30 Amunix Operating Inc Xten conjugate compositions and methods of making same
WO2013142796A2 (en) * 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies

Also Published As

Publication number Publication date
EP3194451A1 (en) 2017-07-26
CN107001484A (en) 2017-08-01
KR20170090406A (en) 2017-08-07
US20160206691A1 (en) 2016-07-21
WO2016041014A1 (en) 2016-03-24
EP3194451A4 (en) 2018-04-25
JP2017534674A (en) 2017-11-24
US20200000877A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
IL250677B (en) Treatment of cancers using anti-nkg2a agents
HUE051354T2 (en) Therapeutic
PL3122358T3 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
IL250387A0 (en) Combination therapy
HK1231561A1 (en) Cancer treatment
GB201405033D0 (en) Combination therapy
ZA201702522B (en) Combination therapy
GB201410216D0 (en) Therapeutic
GB201510637D0 (en) Therapeutic
GB201408297D0 (en) Treatment of cancer
SG11201702122RA (en) Treatment of tumours using peptide-protein conjugates
ZA201608217B (en) Combination therapy
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201414542D0 (en) Novel therapy
GB201417456D0 (en) Treatment of cancer
GB201418500D0 (en) Therapeutic compositions
GB201418299D0 (en) Therapeutic compositions
GB201417465D0 (en) Treatment of cancers
GB201409362D0 (en) Treatment of cancer
GB201418508D0 (en) Therapeutic
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201419311D0 (en) Combination therapy
GB201413719D0 (en) Therapeutic
GB201411570D0 (en) Therapy